


(original)

PATENT CLAIMS

1. Use of glucocorticoid receptor antagonists with a relative binding affinity for the glucocorticoid receptor bond between 85% and 155% of that of dexamethasone and with a relative binding affinity for the progesterone receptor bond between 1% and 11% of that of progesterone or with a 14-fold to 150-fold dissociation between the two receptor types, for the production of a drug for the prophylaxis and therapy of glucocorticoid-mediated hypogonadism, sexual dysfunctions and/or infertility.

(Original)

2. 11β -Substituted steroids as glucocorticoid receptor antagonists of general formula (I)



wherein

R₁ is a methyl, methoxy or ethoxy group and

R₂ is a tert.butyl group, sec.propyl alcohol or sec. propyl ether or a substituted benzene ring.

(Original)

3. 11β -Substituted steroids according to Claim 2,

namely

21-tert.butyl-17-hydroxy- 11β -(3-methoxyphenyl)-19-nor- 17α -pregna-4,9-dien-20-yn-3-one,
methyl-4-{17-hydroxy- 11β -[3-(methoxy)phenyl]-3-keto-19-nor- 17α -pregna-4,9-dien-20-yn-21-yl})
benzoate,

3-{17-hydroxy- 11β -[3-(methoxy)phenyl]-3-keto-19-nor- 17α -pregna-4,9-dien-20-yn-21-
yl})benzaldehyde,

4-{17-hydroxy- 11β -[3-(methoxy)phenyl]-3-keto-19-nor- 17α -pregna-4,9-dien-20-yn-21-yl})

phenylacetate,
17-hydroxy-11 β -[3-(methoxy)phenyl]-21-(4-pyrrolyl)phenyl-19-nor-17 α -pregna-4,9-dien-20-yn-3-one;
17-hydroxy-21-(4-hydroxyphenyl)-11 β -[3-(methoxy)phenyl]-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
17-hydroxy-21-(4-mesylphenyl)-11 β -(3-methoxyphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
21-tert.butyl-17-hydroxy-11 β -(3-ethoxyphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
21-(4-tert.butylphenyl)-17-hydroxy-11 β -(3-methoxyphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
ethyl(E)-3-[17-hydroxy-11 β -(3-methoxyphenyl)-3-keto-19-nor-17 α -pregna-4,9-dien-20-yn-21-yl}
isocrotonate,
21-(3,5-difluorophenyl)-17-hydroxy-11 β -(3-methoxyphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
21-(2-trifluorophenyl)-17-hydroxy-11 β -(3-methoxyphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
21-(3,5-dimethylphenyl)-17-hydroxy-11 β -(3-methoxyphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
4-{17-hydroxy-11 β -[3-(methoxy)phenyl]-3-keto-19-nor-17 α -pregna-4,9-dien-20-yn-21-yl}
phenylsulfamate,
17-hydroxy-21-(1-hydroxy-1-methylethyl)-11 β -(3-methoxyphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
3-(17-hydroxy-3-keto-19-nor-17 α -pregna-4,9-dien-20-yn-11 β -yl)benzaldehyde,
(E)-3-[17-hydroxy-11 β -(3-methoxyphenyl)-3-keto-19-nor-17 α -pregna-4,9-dien-20-yn-21-yl]benzaldoxime,
17-hydroxy-21-(1-methoxy-1-methylethyl)-11 β -(3-methoxyphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
17-hydroxy-21-(4-mesylphenyl)-11 β -(3-methylphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one,
17-hydroxy-21-(4-mesyloxyphenyl)-11 β -(3-methylphenyl)-19-nor-17 α -pregna-4,9-dien-20-yn-3-one, and
4-{17-hydroxy-11 β -[3-methylphenyl]-3-keto-19-nor-17 α -pregna-4,9-dien-20-yn-21-yl}
phenylaminoacetate.

(currently amended)

4. Use of 11 β -substituted steroids as glucocorticoid receptor antagonists according to ~~Claims 2 and 3~~ ^{Claim 2} for producing a drug for the prophylaxis and therapy of glucocorticoid-mediated hypogonadism, sexual dysfunctions and/or infertility.

(currently amended)

Claim 1

5. Use of glucocorticoid receptor antagonists according to ~~Claims 1 to 4~~, characterized in that

the administration occurs orally, subcutaneously, sublingually, in the form of an inhalator or as a plaster, ointment or gel.

(currently amended)

Claim 1

6. Use of glucocorticoid receptor antagonists according to ~~Claims 1 to 5~~ for producing a drug, characterized in that the daily dose to be administered is from 0.01 mg to 100 mg per body weight [sic].